Drug Development Cancer Treatment Weight Loss Drugs Efficacy Studies Rare Diseases Sanofi Mental Health Obesity Treatments HIV Prevention Phase 2 Trials Drug Safety Oncology Treatments Patient Safety PrEP Mpox Treatment Puberty Blockers Depression Treatments Multiple Myeloma Diabetes Treatment Neurological Conditions Drug Approval Drug Supply New Chemical Entities ALS Regulatory Approval Weight Loss Treatments Drug Efficacy Weight Management Psychedelic Research Chronic Conditions HARMONi Trials Pulmonary Arterial Hypertension Epilepsy Treatments Metabolic Diseases Atopic Dermatitis Pulmonary Sarcoidosis Regulatory Approvals Phase II Trials Vaccine Development Phase 2 Dermatology Biosimilarity Obesity Treatment Phase 2 Studies Cancer Treatments Response Rate Drug Effectiveness Phase 3 Trials Semaglutide Candidates GLP-1s Competition Phase 3 Ketamine Weight-Loss Drugs
The company set an FDA end-of-Phase-2 meeting for Q2 2026 ahead of a planned Phase 3 start in the second half of the year.
